Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1142 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

NCT03129646

Visceral Leishmaniasis

COMPLETED PHASE3

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

NCT01067443

Primary Visceral Leishmaniasis

COMPLETED PHASE2

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

NCT05957978

Primary Visceral Leishmaniasis

COMPLETED PHASE2

Sodium Stibogluconate Treatment of Leishmaniasis

NCT00662012

Leishmaniasis

COMPLETED PHASE2

Use of Sodium Stibogluconate as a Treatment for Leishmaniasis

NCT00657618

Leishmaniasis

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently in the three countries, Sudan, Kenya and Ethiopia many of the patients present themselves in remote areas and need to be treated in relative resource poor settings. It is for this reason that standardised treatment with proven efficacy is much needed. A shorter course of treatment is not only advantageous for the patient but also reduces the overall case load in the clinics thus reducing the risk of disease outbreaks in already immuno-compromised kala-azar patients. Paromomycin, either alone or in combination with SSG would decrease the treatment duration substantially. An additional added value of combination therapy is that it is likely to reduce the chances of development of parasite resistance against the individual drugs.

Leishmaniasis experts in the three countries are in agreement that there are potential benefits of the combination treatment of SSG and PM and that its efficacy should be evaluated with the view to introduce this protocol if proven efficacious and safe. There is ample circumstantial evidence of the use of this combination therapy and its efficacy and tolerability as a standardized protocol. This can only be confirmed through a randomised controlled study with 6 months follow up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visceral Leishmaniasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Sodium Stibogluconate (30 days)

Group Type ACTIVE_COMPARATOR

Sodium Stibogluconate

Intervention Type DRUG

Sodium Stibogluconate 20mg/kg/day for 30 days

2

Paromomycin Sulphate (21 days)

Group Type EXPERIMENTAL

Paromomycin sulphate

Intervention Type DRUG

Paromomycin sulphate

3

Sodium Stibogluconate + Paromomycin Sulphate (17 days)

Group Type EXPERIMENTAL

SSG and Paromomycin sulphate

Intervention Type DRUG

SSG and Paromomycin Sulphate 17 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sodium Stibogluconate

Sodium Stibogluconate 20mg/kg/day for 30 days

Intervention Type DRUG

Paromomycin sulphate

Intervention Type DRUG

SSG and Paromomycin sulphate

SSG and Paromomycin Sulphate 17 days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients for whom written informed consent has been signed by the patients themselves (if aged 18 years and over) or by parents(s) or legal guardian for patients under 18 years of age.
2. Patients aged between 4 and 60 years (inclusive) who are able to comply with the protocol. It is justified to include children because they represent more than 50% of VL cases.
3. Patients with clinical signs and symptoms of VL and diagnosis confirmed by visualization of parasites in tissue samples (spleen, lymph node or bone marrow) on microscopy.

Exclusion Criteria

1. Patients who have received any anti-leishmanial drug in the last 6 months.
2. Patients with a negative splenic / lymph node / bone marrow smears.
3. Patients with a clinical contraindication to splenic/lymph node/ bone marrow aspirates.
4. Patients with severe protein and or caloric malnutrition (Kwashiokor or marasmus)
5. Patients with previous hypersensitivity reaction to SSG or aminoglycosides.
6. Patients suffering from a concomitant severe infection such as TB or any other serious underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the patients response to study medication.
7. Patients suffering from other conditions associated with splenomegaly such as schistosomiasis.
8. Patients with previous history of cardiac arrhythmia or an abnormal ECG
9. Patients who are pregnant or lactating.
10. Patients with haemoglobin \< 5gm/dl.
11. Patients with WBC \< 1 x 10³/mm³.
12. Patients with platelets \< 40,000/mm³.
13. Patients with liver function tests more than three times the normal range
14. Patients with serum creatinine outside the normal range for age and gender
15. Patients with pre-existing clinical hearing loss.

Minimum Eligible Age

4 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No